Too Many Chest CTs for Incidental Lung Nodules?

Published Date: 16 May 2026

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

Read Full News

Latest News

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Todays Updates

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Todays Updates

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Latest News

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

News All Time

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Recommended News For You

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

Future of Lab-Developed Tests Still Taking Shape

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

New protein target discovered for childhood medulloblastomas

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

Recommended Articles For You

Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning 

Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

2.

The Effect of Common Steroids on Cancer Treatments.

3.

Study sheds light on challenges for women of color after breast cancer surgery

4.

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

5.

Research discovery halts childhood brain tumor before it forms

1.

The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia

2.

Polyposis Syndrome: Causes, Symptoms, and Treatment Options

3.

Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients

4.

IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity

5.

Unveiling the Hidden Benefits of Lymphedema Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

3.

Navigating the Complexities of Ph Negative ALL - Part XIII

4.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot